MOG and glioblastoma: Choe et al. used this technique to develop a synNotch CAR T cell against GBM, whereby first the synNotch receptor recognizes either a GBM-specific antigen (EGFRvIII) or CNS-specific antigen (MOG), priming the cell to then express a tandem CAR targeting GBM antigens, EphA2 and IL13Rα2 [97].